Dermatologic complications associated with administration of 2′,3′-dideoxycytidine in patients with human immunodeficiency virus infection

McNeely, M. Carol; Yarchoan, Robert; Broder, Samuel; Lawley, Thomas J.

doi:10.1016/s0190-9622(89)70332-7

Cited by 60 publications

(12 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Clinicians must monitor patients closely to detect symptoms early and to modify treatment in order to minimize its negative impact on quality of life. Other adverse effects include ulcerative stomatitis, which was described in 3%-17% of patients from various studies [54,55] and unlike other NRTIs, zalcitabine is associated with a maclopapular rash involving the trunk and extremities [56].…”

Section: Nucleoside Reverse Transcriptase Inhibitors (Nrtis)mentioning

confidence: 99%

Management of the Adverse Effects of Antiretroviral Therapy and Medication Adherence

Max¹,

Sherer²

2000

Clinical Infectious Diseases

181

142

View full text Add to dashboard Cite

A commonly cited cause of poor adherence to highly active antiretroviral therapy (HAART) is adverse drug reactions. Short-term adverse effects are potential threats to successful introduction and maintenance of HAART. The long-term toxicities of HAART are still emerging and being defined, as evidenced by the recently described metabolic disorders (i.e., the syndrome of maldistribution, hyperlipemia, glucose intolerance and insulin resistance). With 14 licensed agents in 2000, other agents in common use, and numerous combinations of >/=3 drugs, awareness and recognition of adverse effects are increasingly important for clinicians and patients. The common adverse drug reactions encountered with HAART, including new agents and their impact on patient adherence, are reviewed. Current strategies to anticipate and mitigate adverse effects are summarized.

show abstract

Section: Nucleoside Reverse Transcriptase Inhibitors (Nrtis)mentioning

confidence: 99%

Management of the Adverse Effects of Antiretroviral Therapy and Medication Adherence

Max¹,

Sherer²

2000

Clinical Infectious Diseases

181

142

View full text Add to dashboard Cite

show abstract

“…Erythema multiforme (Creagh-Kirk et al, 1988) and toxic epidermal necrolysis are especially well recognized in HIV disease, particularly as reactions to sulphonamides and to antiretroviral agents (Bayard et al, 1992). Erythema multiforme has been seen with many of the NRTIs, oral ulceration being recorded particularly with zalcitabine (dideoxycytidine) which produces mouth ulcers in from 3-30% of patients (McNeely et al, 1989;Adkins et al, 1997). Fortunately these ulcers resolve at the latest by the third week of therapy, or if the drug is withdrawn and they do not develop in patients given only low doses of zalcitabine (McNeely et al, 1989).…”

Section: Possible Orofacial Adverse Effects Of Nrtismentioning

confidence: 99%

Orofacial effects of antiretroviral therapies

Scully¹,

Dios²

2001

Oral Diseases

View full text Add to dashboard Cite

This paper summarises some of the oral adverse effects of antiretroviral agents. Some are related to bone marrow suppression which may also predispose to mouth ulcers. Erythema multiforme and toxic epidermal necrolysis are especially well recognized in HIV disease, particularly as reactions to sulphonamides and to antiretroviral agents. Oral lichenoid reactions have been described in HIV disease often relating to zidovudine use. Didanosine has also produced erythema multiforme and not unusually induces xerostomia, again by an unknown mechanism. Xerostomia may be seen in up to one-third of patients taking didanosine. Taste abnormalities are common with the protease inhibitors and oral and perioral paraesthesia can be a disturbing adverse effect. Ritonavir in particular can give rise to circumoral paraesthesia in over 25% of patients. Indinavir can also produce cheilitis.

show abstract

“…39 Initial clinical trials documented mucocutaneous eruptions in 70% of patients (14 of 20) who received high dosages of this drug (0.03-0.25 mg/kg every 4-8 hours). 40 Current therapeutic dosage recommendations are lower (0.75 mg orally every 8 hours), 15 but severe rash and stomatitis are still documented side effects (2% and 4% incidence, respectively). 16 A case of lichenoid eruption with eosinophilia was reported recently in regard to tenofovir.…”

Section: Emtricitabinementioning

confidence: 99%

Adverse Cutaneous Reactions to Antimicrobials in Patients with Human Immunodeficiency Virus Infection

Miller¹,

Warshaw²

2007

Dermatitis

View full text Add to dashboard Cite

Adverse reactions to medication are significant contributors to morbidity and mortality in patients with human immunodeficiency virus (HIV) infection. Cutaneous events not only constitute a significant portion of these reactions, they may also herald developing systemic reactions such as hemato-, nephro-, and hepatotoxicity. The identification of cutaneous adverse reactions and drug culprits and the proper management of reactions are of paramount importance for these patients. This review focuses specifically on adverse cutaneous reactions to antimicrobials that are commonly used in the management of patients with HIV infection.

show abstract

Dermatologic complications associated with administration of 2′,3′-dideoxycytidine in patients with human immunodeficiency virus infection

Cited by 60 publications

References 13 publications

Management of the Adverse Effects of Antiretroviral Therapy and Medication Adherence

Management of the Adverse Effects of Antiretroviral Therapy and Medication Adherence

Orofacial effects of antiretroviral therapies

Adverse Cutaneous Reactions to Antimicrobials in Patients with Human Immunodeficiency Virus Infection

Contact Info

Product

Resources

About